Igeneon: Staying Close to Home
Igeneon's latest in-licensing rounds out its cancer immunotherapy pipeline with another compound its founders know well. IGN 301, an epithelial cancer vaccine, is the second of Igeneon's three clinical projects to originate from Novartis. Both were discovered under the guidance of Igeneon's founders, who have a combined 50 years' experience at the Swiss giant.
You may also be interested in...
European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.
Pharmacia spin-off Biovitrum, like other biotechs born out of Big Pharma, has found favor with investors seeking experienced management and advanced programs. But Biovitrum's size, cash flow, and independence appear to make it more attractive still.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.